Phase 2 study of parsaclisib (INCB050465), a highly selective, next-generation PI3Kδ inhibitor, in relapsed or refractory diffuse large B-cell lymphoma (CITADEL-202).

导出 LinkOut

翻译打印收藏纠错

作者： Morton,Coleman ^[1] ; David,Belada ^[2] ; René-Olivier,Casasnovas ^[3] ; Rémy,Gressin ^[4] ; Hui-Peng,Lee ^[5] ; Amitkumar,Mehta ^[6] ; Javier,Munoz ^[7] ; Gregor,Verhoef ^[8] ; Claudia,Corrado ^[9] ; Douglas J,DeMarini ^[10] ; Wanying,Zhao ^[10] ; Jia,Li ^[10] ; Keith,Fay ^[10]

作者单位： Clinical Research Alliance/Weill Cornell Medicine, New York, NY, USA. ^[1] 4th Department of Internal Medicine - Haematology, Charles University, Hospital and Faculty of Medicine, Hradec Králové, Czech Republic. ^[2] University Hospital F. Mitterrand and Inserm UMR 1231, Dijon, France. ^[3] Department of Oncohaematology, University Hospital Grenoble-Alpes, Grenoble, France. ^[4] Institute for Advanced Biosciences, Inserm U 823, Grenoble, France. ^[5] Flinders Medical Centre, Bedford Park, SA, Australia. ^[6] UAB School of Medicine, Birmingham, AL, USA. ^[7] Banner MD Anderson Cancer Center, Gilbert, AZ, USA. ^[8] Department of Hematology, University Hospitals Leuven, Leuven, Belgium. ^[9] Incyte Corporation, Wilmington, DE, USA. ^[10] Department of Haematology, St Vincent's Hospital, Darlinghurst, NSW, Australia. ^[11]

关键词 B-cell lymphoma DLBCL INCB050465 PI3Kδ inhibitor non-Hodgkin lymphoma parsaclisib

主题词人类(Humans);淋巴瘤, 大B细胞, 弥漫性(Lymphoma, Large B-Cell, Diffuse);吡唑类(Pyrazoles);嘧啶类(Pyrimidines);吡咯烷类(Pyrrolidines)

DOI 10.1080/10428194.2020.1832660

PMID 33140664

发布时间 2021-04-27

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交